Isunakinra is under clinical development by Buzzard Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Isunakinra’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Isunakinra Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Isunakinra (EBI-005) was under development for the treatment of moderate to severe allergic conjunctivitis and solid tumors. The drug candidate is administered through ophthalmic route. It acts by targeting interleukin-1 (IL-1) receptor. It is developed based on AMP-Rx protein engineering platform. It was also under development for severe ocular allergy and dry eye disease.
Quick View Isunakinra LOA Data
|Highest Development Stage|